Cyteir Therapeutics
Cyteir Therapeutics is a clinical-stage oncology company developing CYT-0851, an oral small molecule inhibitor of monocarboxylate transporters, for the treatment of patients with advanced solid tumors, with priority on advanced ovarian cancer in a Phase 1/2 trial.
- Company typePrivate
- Founded2012
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cyteir Therapeutics does
Cyteir Therapeutics, Inc. is a clinical-stage oncology company developing synthetic lethal therapies for cancer, with operations headquartered at 99 Hayden Ave., Building B, Suite 450, Lexington, Massachusetts. Founded in 2012, the company is focused on a single lead investigational drug candidate, CYT-0851, an oral small molecule inhibitor of monocarboxylate transporter (MCT) activity. MCT inhibition targets a metabolic vulnerability in cancer cells and is being explored as a treatment for patients with advanced solid tumors, with priority development in advanced ovarian cancer. Cyteir has initiated a Phase 1/2 clinical trial (NCT03997968) evaluating CYT-0851 in combination with the chemotherapy agents capecitabine and gemcitabine.
The company's technology platform is built around proprietary small molecule chemistry directed at monocarboxylate transporters, with CYT-0851 described in company materials as a potent, novel inhibitor of MCT activity. Cyteir holds the registered "Cyteir" trademark and is led by co-founders Kevin Mills and Tim Romberger, supported by CSO Paul Secrist and vice presidents across chemistry, R&D project leadership, and regulatory affairs and quality. Scientific co-founders and an institutional investor base that has historically included Celgene (now Bristol Myers Squibb) indicate early strategic validation of the synthetic lethal approach from big-pharma oncology.
Cyteir is pre-revenue and generates no commercial product sales. Its business model is structured around clinical development of CYT-0851 through eventual FDA approval and commercialization, at which point revenue would be generated through pharmaceutical sales channels (specialty pharmacies and oncology clinics) and/or licensing arrangements. To date, the company has financed operations through approximately $156.7 million in disclosed equity and grant funding across rounds from 2015 through 2021, with its go-to-market motion being patient enrollment in its Phase 1/2 study via clinicaltrials.gov and clinical trial sites rather than commercial sales activity.
Cyteir Therapeutics firmographics
Firmographics- Name
- Cyteir Therapeutics
- Legal name
- Cyteir Therapeutics, Inc.
- Website
- https://cyteir.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cyteir Therapeutics is a clinical-stage oncology company developing CYT-0851, an oral small molecule inhibitor of monocarboxylate transporters, for the treatment of patients with advanced solid tumors, with priority on advanced ovarian cancer in a Phase 1/2 trial.
- Ownership category
- akta.pro rank
Cyteir Therapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- akta.pro primary industry
- Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
Keywords
Where Cyteir Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cyteir Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Development Revenue: Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through drug commercialization upon FDA approval, likely through prescription-based sales of CYT-0851 for treatment of advanced solid tumors including ovarian cancer.
Distribution channels1 record
Marketing channels1 record
Cyteir Therapeutics product offering
Product offeringCore offering
Cyteir Therapeutics is a clinical-stage oncology company developing CYT-0851, an oral investigational small molecule inhibitor of monocarboxylate transporter activity. The lead candidate is being advanced in a Phase 1/2 clinical study in combination with capecitabine and gemcitabine, with current priority indication in advanced ovarian cancer and broader application across advanced solid tumors.
Product overview
Cyteir Therapeutics is a clinical-stage oncology company with a focused product portfolio centered on CYT-0851, its lead investigational drug candidate. CYT-0851 is a novel small molecule inhibitor of monocarboxylate transporter activity being developed for the treatment of advanced solid tumors, with current priority development in combination with chemotherapy agents capecitabine and gemcitabine in a Phase 1/2 clinical study for advanced ovarian cancer.
Differentiator
Problem solved
Functional benefit
Products and services
- CYT-0851
Companies that use Cyteir Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Cyteir Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Cyteir Therapeutics partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Cyteir Therapeutics competitors and assessment
Company assessmentEmerging players
- Nuvalent: Clinical-stage oncology company developing targeted small molecule therapies. Similar profile as a clinical-stage precision oncology biotech.
- Erasca: Clinical-stage precision oncology company developing small molecules targeting the RAS/MAPK pathway. Comparable clinical-stage small molecule oncology development.
- Arcus Biosciences: Clinical-stage oncology company developing small molecule immuno-oncology therapies. Comparable clinical-stage oncology small molecule pipeline profile.
- Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin biology with small molecules. Comparable profile as a small molecule-focused clinical-stage oncology biotech.
Direct peers
- Black Diamond Therapeutics: Clinical-stage oncology company developing small molecule therapies against novel targets in cancer. Comparable small molecule oncology drug development profile.
- Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethal therapies targeting DNA damage response. Direct competitor in the synthetic lethal oncology space.
- Tango Therapeutics: Clinical-stage oncology company built around synthetic lethal target discovery and small molecule development. Highly comparable to Cyteir's synthetic lethal approach targeting cancer vulnerabilities.
- IDEAYA Biosciences: Clinical-stage synthetic lethal and precision oncology company developing small molecules against genetically defined patient populations. Comparable mechanism-driven oncology approach.
Broad incumbents
- AstraZeneca: Global pharmaceutical company with established PARP inhibitor franchise (Lynparza) and broader oncology small molecule portfolio. Relevant broad incumbent in synthetic lethal and targeted oncology.
- Schrodinger: Computational drug discovery company with internal pipeline of small molecule oncology programs. Broader platform player overlapping in small molecule oncology R&D.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Cyteir Therapeutics social profiles
Digital presenceCyteir Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyteir Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
Cyteir Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyteir Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyteir Therapeutics
What does Cyteir Therapeutics do?
Cyteir Therapeutics is a clinical-stage oncology company developing CYT-0851, an oral investigational small molecule inhibitor of monocarboxylate transporter activity. The lead candidate is being advanced in a Phase 1/2 clinical study in combination with capecitabine and gemcitabine, with current priority indication in advanced ovarian cancer and broader application across advanced solid tumors.
Is Cyteir Therapeutics a public or private company?
Cyteir Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cyteir Therapeutics founded?
Cyteir Therapeutics was founded in 2012. It employs 11 to 50 people.
Where is Cyteir Therapeutics based?
Cyteir Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Cyteir Therapeutics make money?
One revenue line is on record: pharmaceutical Development Revenue.
Who are Cyteir Therapeutics's main competitors?
Emerging players on record are Nuvalent, Erasca, Arcus Biosciences and Foghorn Therapeutics. Direct peers are Black Diamond Therapeutics, Repare Therapeutics, Tango Therapeutics and IDEAYA Biosciences. Broad incumbents are AstraZeneca and Schrodinger.
Does Cyteir Therapeutics have an API?
No public API is recorded for Cyteir Therapeutics.
What industry is Cyteir Therapeutics in?
Cyteir Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 5417.